ProtoKinetix, Inc.
ProtoKinetix, Inc. is a U.S.-based biotechnology company focused on research and development of AFGPs, or anti-freeze glycoproteins, marketed under the AAGP® trademark. The company’s work centers on advancing this molecule toward commercial use in targeted healthcare and other medical applications, with research, validation, and partnering activities as core parts of the business.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaScientific work to validate and advance the AAGP® molecule for medical use.
Activities to secure collaborators and commercial entities for market entry.
Patent-related work and protection of the AAGP® technology platform.
Asiakkaat
ProtoKinetix does not appear to sell a broad commercial product set today; instead, its counterparties are mainly researchers, advisors, business partners, and potential commercial entities involved in validating AAGP®. If the technology is commercialized, the end customers would likely be healthcare organizations and other users of targeted medical solutions. The company’s current “customers” are therefore more partnership-oriented than traditional product buyers.
Universities, labs, and scientific partners that help test and validate AAGP®.
Business entities that may help fund, license, or commercialize AAGP®.
Future buyers of targeted health care applications built on AAGP®.
Institutions that may support continued studies through grants or programs.
Strategia
The company’s strategy is to move AAGP® from scientific research toward practical commercial validation and eventual market use. It is also seeking research partners, grant-supported institutes, and commercial entities to share development costs and improve the path to commercialization.
The molecule must be validated before it can support meaningful commercialization.
External partners can reduce funding needs and accelerate development.
Longer-term value depends on turning the molecule into marketable applications.
Maantiede
ProtoKinetix is headquartered in the United States and reports U.S. GAAP financial statements. The filings also reference Canada in the context of tax exposure, suggesting some cross-border business or planning considerations, but the company’s operating footprint appears centered in North America. Geography matters mainly through research collaboration, tax treatment, and the location of future commercialization partners rather than through a broad manufacturing network.
Riskit
ProtoKinetix faces the typical risks of an early-stage biotechnology company: uncertain scientific outcomes, dependence on external funding, and a long path from research to commercialization. Company-specific risks also include retaining key scientific consultants, protecting intellectual property, and managing common stock volatility while funding operations through equity issuance.
The company has limited cash and relies on external financing to continue operations.
Kohdistuu: Operating continuity and development funding
AAGP® may not achieve the validation needed for commercial use.
Kohdistuu: Core technology and future monetization
The company intends to fund itself by selling common stock.
Kohdistuu: Shareholder dilution and financing terms
The business depends on specialized expertise to advance research.
Kohdistuu: Execution of research and commercialization plans
Competing technologies or weak IP protection could limit adoption.
Kohdistuu: AAGP® market position
Kirjanpito
Harkinnanvaraiset erätWarrants and options issued for services are measured using Black-Scholes, which depends on assumptions.
Vaikutus: Can materially affect operating expenses and equity
Patent application billings and molecule-related costs affect cash use and development intensity.
Vaikutus: Affects investing cash flow and period expenses
Limited cash and recurring losses require management judgment about continuation.
Vaikutus: Important for liquidity interpretation and disclosure
U.S. GAAP requires management estimates for uncertain items and service-based awards.
Vaikutus: Can change reported expenses and financial condition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Cytokinetics, Incorporated
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Aibotics, Inc.
AIBT · Medicinal Chemicals & Botanical Products
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
Päivitetty: 24.9.2026